Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11408843 | 0.89 | MAPT (0.83) | CYP19A1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL10987231 | 0.88 | MAPT (0.71) | CYP19A1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL11510257 | 0.88 | MAPT (0.71) | CYP19A1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL10557875 | 0.84 | MAPT (0.75) | CYP19A1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL11608031 | 0.84 | MAPT (0.75) | CYP19A1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL18415556 | 0.84 | RAB9A (0.68) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL7556396 | 0.83 | NPC1 (0.69) | ALDH1A1KDM4EHPGDMAPTNPC1 | |
| SCHEMBL626949 | 0.83 | MAPT (0.73) | CYP19A1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL11536521 | 0.83 | HPGD (0.73) | CYP19A1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL9674962 | 0.82 | CYP19A1 (0.52) | CYP19A1ALDH1A1KDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3966965-A | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-06-29 | — | — | US | claimed |
| US-20250092001-A1 | NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME | UNIV DREXEL (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4469440-A1 | NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME | Drexel University (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118946550-A | Novel excitatory amino acid glutamate transport modulators and methods of use thereof | 德雷克塞尔大学 | 2024-11-12 | — | — | CN | disclosed |
| WO-2023146831-A1 | NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME | DREXEL UNIVERSITY (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-115611793-A | Method for synthesizing thioamide compound | 山东新华制药股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2012087889-A2 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-4191840-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-03-04 | — | — | US | disclosed |
| US-4160100-A | OXAMIC ACID DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4154961-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4137325-A | Antisecretory oxamic acid esters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-01-30 | — | — | US | disclosed |
| US-4099007-A | N,N-SUBSTITUTED 2,4,5-TRIKETOIMIDAZOLIDINES AND A PROCESS FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-07-04 | — | — | US | disclosed |
| US-4069343-A | OXAMIC ACID DERIVATIVES FOR THE PREVENTION OF IMMEDIATE TYPE HYPERSENSITIVITY REACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4054661-A | Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054657-A | Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054666-A | Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4036837-A | 2 Alkoxyoxamoyl-pyrazines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-3966965-A | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | MECP2, DNMT1, DNMT3B | CYP19A1 1708/4885ALDH1A1 2789/4885KDM4E 427/4885 |
| US-20250092001-A1 | NOVEL EXCITATORY AMINO ACID GLUTAMATE TRANSPORT MODULATORS AND METHODS USING THE SAME | SLC1A2, SLC1A3, SLC1A1 | CYP19A1 4528/4885ALDH1A1 1199/4885KDM4E 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.